RxDoctor Payments Data

Paul Betschart, DPM

Podiatrist · Danbury, CTNPI 1639270044

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,957 of the $9,705 with a category attached, or 71.7%. Treace Medical Concepts, Inc. accounts for 85.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $5,946, more than ten times the $271 reported in 2019. Among podiatrist clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,705in general payments, 2019–2025

Across 53 payments — averaging $183.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$8K
  • Smith+Nephew$495
  • Organogenesis Inc.$295
  • Stryker$201
  • Averitas Pharma Inc.$145
  • Shockwave Medical, Inc$110
  • plus $205 from 7 others

What the payments were for

  • Travel & lodging$6,95772%
  • Food & beverage$2,65527%
  • Gifts$941%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,705 in reported general payments places this provider in the 95th percentile of 119 podiatrist providers in Connecticut.

See all podiatrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$215,886
Medicare patients
649
Services billed
5,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser14$50,686
Terbinafine Hcl118$1,365
Lidocaine13$920
Gabapentin16$270
Ammonium Lactate12$263
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$177
Cefadroxil24$167
Pregabalin18$105
Meloxicam19$58
Tramadol Hcl13$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GRT US Holding, Inc.Qutenza$22$50,68614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 119 podiatrist providers in Connecticut.

Other podiatrist in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →